Pelago Bioscience was founded in 2013 with the aim to develop the patented Cellular Thermal Shift Assay (CETSA®) for maximum utility and customer value in drug discovery and diagnostics. Today, Pelago Bioscience is a Drug Discovery Research Partner supporting preclinical drug discovery and development. Pelago offer a range of services, from confirming target engagement to strengthening target validation and understanding the mechanism of action of your compounds. The approach is designed to help you make better decisions faster.
Target Deconvolution service based on proteome-wide Cellular Thermal Shift Assay using Mass Spectrometry detection is performed in intact cells and lysate without any compound modifications.
Hit confirmation service is based on the Cellular Thermal Shift Assay (CETSA) and allows for assessment of compound binding to a selected target protein in its native state without any modifications to the protein or the compound.
Primary screening based on Cellular Thermal Shift Assay (CETSA) allows for rapid identification of high quality chemical starting points against the native, full-length protein in live cells.
